← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Velum, Inc.
Cambridge, MA
$5,415,069
Total funding
8
Grants
Funding over time
peak $1.3M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,415,069 · 8
By mechanism
R42$3,800,047 · 2
R41$1,615,022 · 6
Investigators at Velum, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome$1,135,509
R42 · FY2024 · DK
A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome$959,031
R42 · FY2025 · DK
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1$738,741
R42 · FY2022 · AG
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1$488,486
R42 · FY2021 · AG
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1$478,280
R42 · FY2023 · AG
Protease Stable N-Terminally Modified Therapeutic Peptides$367,389
R41 · FY2022 · DK
Peptide YY triagonist weight loss drugs$315,342
R41 · FY2025 · DK
Triagonist Peptide Therapeutics for Neuroprotection$259,613
R41 · FY2021 · GM
Rapid High-Fidelity Assembly of Challenging Peptide Sequences$225,000
R41 · FY2019 · GM
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1$225,000
R41 · FY2018 · AG
Design of Protease Stable Therapeutic Peptides by Non-Perturbative Modification$222,678
R41 · FY2018 · GM